
### [Orphanet:90077](http://www.orpha.net/ORDO/Orphanet_90077)
**Label:** Other acquired skin disease

**Subclasses:** [Orphanet:820](http://www.orpha.net/ORDO/Orphanet_820) (Sneddon syndrome), [Orphanet:1221](http://www.orpha.net/ORDO/Orphanet_1221) (Cheilitis glandularis), [Orphanet:3243](http://www.orpha.net/ORDO/Orphanet_3243) (Sweet syndrome), 

**Corr. equiv. classes:** [Orphanet:1221](http://www.orpha.net/ORDO/Orphanet_1221), [OMIM:608068](http://purl.obolibrary.org/obo/OMIM_608068), [Orphanet:3243](http://www.orpha.net/ORDO/Orphanet_3243), [OMIM:182410](http://purl.obolibrary.org/obo/OMIM_182410), [OMIM:118330](http://purl.obolibrary.org/obo/OMIM_118330), [Orphanet:820](http://www.orpha.net/ORDO/Orphanet_820), 

**Class expressions from DL-Learner:**

- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0100543](http://purl.obolibrary.org/obo/HP_0100543) (Cognitive impairment) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0011804](http://purl.obolibrary.org/obo/HP_0011804) (Abnormality of muscle physiology) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0011446](http://purl.obolibrary.org/obo/HP_0011446) (Abnormality of higher mental function) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0011442](http://purl.obolibrary.org/obo/HP_0011442) (Abnormality of central motor function) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0010549](http://purl.obolibrary.org/obo/HP_0010549) (Weakness due to upper motor neuron dysfunction) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0004374](http://purl.obolibrary.org/obo/HP_0004374) (Hemiplegia/hemiparesis) 66.67%
- [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) and [HP:0004305](http://purl.obolibrary.org/obo/HP_0004305) (Involuntary movements) 66.67%
- [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%
- [HP:0002493](http://purl.obolibrary.org/obo/HP_0002493) (Upper motor neuron dysfunction) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%
- [HP:0002315](http://purl.obolibrary.org/obo/HP_0002315) (Headache) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%
- [HP:0002167](http://purl.obolibrary.org/obo/HP_0002167) (Neurological speech impairment) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%
- [HP:0001337](http://purl.obolibrary.org/obo/HP_0001337) (Tremor) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%
- [HP:0001324](http://purl.obolibrary.org/obo/HP_0001324) (Muscle weakness) and [HP:0003613](http://purl.obolibrary.org/obo/HP_0003613) (Antiphospholipid antibody positivity) 66.67%


